Selank
No double-blind, placebo-controlled trial found.
A sibling of Semax from the same Russian institute, registered in Russia for anxiety. Elsewhere it is sold as a calming nasal spray that does not sedate. We found no double-blind, placebo-controlled trial. Also called TP-7.
What the evidence shows
Side effects and risks
Who should avoid it: Treat it as untested.
How it works
- Where it acts
- Thought to influence GABA signalling and slow the breakdown of enkephalins, the brain's calming peptides.
- What it changes
- In animals and small Russian studies, less anxiety without sedation.
- What people notice
- Calm without drowsiness is what users report. Strong trial evidence is lacking.
How it has been given in studies
The trial used 2.7 mg a day for two to three weeks. In Russia it is sold as nose drops.
Getting it in the United States
The legal route for Selank
Not FDA-approved and not eligible for pharmacy compounding. Vials sold for research use only are unapproved drugs when marketed for people.
Routes people use for any peptide in the United States
Telehealth prescribing
Online clinics prescribe after a questionnaire, sometimes with no live doctor visit, and mail the drug. FDA moved in February 2026 to restrict mass-marketed compounded copies and claims that they are generic equivalents.
Risk: Thin medical screening. Compounded versions are not reviewed by FDA for quality.
Covers: Approved GLP-1 drugs, compounded semaglutide and tirzepatide
Source: GZERO Media, Apr 2026
Clinical trial enrolment
The only lawful way to get an unapproved peptide drug with medical monitoring. ClinicalTrials.gov lists eligibility, sites and phone numbers. Researchers note recruitment is hard when people can buy the drug on the gray market instead of risking placebo.
Risk: Possible placebo assignment, strict eligibility and travel to a study site.
Covers: Investigational peptide drugs still in development
Source: NIH, finding a clinical trial
Compounding pharmacy with prescription
Kennedy said Selank would return to the compounding-allowed category in 2026. That status is not approval and gives no validated uses or dosing. FDA still lists immune-reaction concerns for Selank.
Source: AJMC, 2026-08
Research-use-only online sellers
A regulatory lawyer says thousands of online companies sell peptides labeled for research purposes only to sidestep federal rules. He expects price-sensitive buyers to keep using them even if compounding returns.
Source: PharmaVoice, 2026-04
Routes people use for any peptide in the United States
Compounding pharmacy with prescription
A clinician prescribes and a pharmacy compounds. Twelve peptides left the FDA do-not-compound category in April 2026 and a panel backed six in July, but they are not yet formally eligible. Pharmaceutical-grade ingredient is scarce.
Risk: Legal status is unsettled until FDA rulemaking ends. Pharmacies may use research-grade ingredient.
Covers: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and similar
Source: Frier Levitt, Apr 2026
Med spas and weight-loss clinics
Very common. Secret shoppers called 75 clinics and med spas in two states after shortages ended. 92 percent offered compounded semaglutide and 87 percent tirzepatide, often mixed with B vitamins to look custom.
Risk: Four of 23 suppliers lacked sterile compounding licenses and four had disciplinary records.
Covers: Compounded semaglutide and tirzepatide
Source: American Med Spa Association on JAMA Health Forum study, Jul 2026
Concierge and longevity doctors
Cash-pay physicians build peptide plans for wealthy clients. Reporting from San Francisco says some source from overseas channels, domestic research-use-only sellers or the few compounding pharmacies that will supply clinicians.
Risk: A doctor's involvement does not guarantee a pharmaceutical-grade product.
Covers: BPC-157, thymosin alpha-1, Selank, Semax, CJC-1295, ipamorelin, retatrutide
Source: San Francisco Standard, Sep 2025
Cross-border purchase or import
FDA says importing drugs for personal use is illegal in most cases but it may not object to small personal quantities in limited situations. Reporting also describes people travelling to Mexico for injections.
Risk: Packages can be seized. Product origin and cold-chain handling are hard to check.
Covers: Approved prescription peptides sold abroad
Source: FDA, personal importation
Routes people use for any peptide in the United States
Research-chemical websites
Sites sell vials marked for research or not for human consumption, with no prescription. FDA says some ship direct to consumers with dosing directions, and it has sent warning letters. Retatrutide exists only through this route or trials.
Risk: Unknown identity, strength and sterility. No pharmacist or prescriber involved.
Covers: Retatrutide, semaglutide, tirzepatide, BPC-157 and most unapproved peptides
Source: FDA, unapproved GLP-1 drugs page
Direct orders from Chinese factories
Buyers message factory sales agents and pay by crypto or payment app. A minimum order of about ten vials pushes people to buy in bulk and share. A blockchain analysis found US buyers were the largest source of funds.
Risk: Many of the same vendors list fentanyl precursors. Lab reports sent by sellers cannot be verified.
Covers: GLP-1 copies, melanotan II, BPC-157, TB-500, GHK-Cu, epitalon
Source: TRM Labs, Oct 2026
Chat groups and social sellers
Dealers are found through Telegram, WhatsApp, Discord and influencer discount codes. In a May 2026 survey of 1,000 US users, 14.5 percent bought this way and three quarters asked an AI chatbot for dosing.
Risk: 45 percent of social media buyers in that survey reported an emergency or urgent care visit for a reaction.
Covers: Retatrutide and other research-use-only peptides
Source: The Ethos, May 2026
This describes what people do. It is not advice. The decision is yours.
What users report
Recurring themes in public forum posts, unverified and with no comparison group.
Reported benefits
- Calm without drowsiness
Reported problems
- Mild, and fades with use
- Tiredness
- Nothing at all
More contextWhat public figures say, videos and articles, when options run out and the chemistry
What experts and influencers say
Paraphrased from the linked sources.
Lists Selank acetate among compounding substances with possible safety risks. Cites possible immune reactions from aggregation and impurities and says it lacks important human safety information.
US Food and Drug AdministrationSourceWarns against
Reported to have personally used Semax and Selank. Said on a podcast that returning restricted peptides to legal compounding would move buyers to ethical suppliers.
Source: PharmaVoice, 2026-04
Robert F. Kennedy Jr.InstagramRecommendsSays they used it
Describes Selank as mainly an anti-anxiety peptide and Semax as mainly a nootropic. Notes that the popular practice of combining the two has no clinical trial data.
Source: Dr Bliss Lewis site, 2026-04
Bliss LewisInstagramMixed view
Said there is justification for all the restricted peptides to stay restricted because they are not pharmaceutical grade. Warned that reclassifying them could falsely signal that untested compounds are safe.
Source: PharmaVoice, 2026-04
Edgar AsebeyWebsiteWarns against
Photo source: frierlevitt.com
Told a reporter she takes four peptide injections a day, tests everything on herself before recommending it and found Selank the standout.
Source: San Francisco Standard, Sep 2025
Molly MaloofWebsiteRecommendsSays they used it
Photo source: a4m.com
Commenting on the peptide reclassification that includes Selank, said patient demand is not clinical evidence but cannot be ignored, and warned against an unregulated market carrying a pharmacy label.
Source: AJMC, 2026-08
Rachel StraussWebsiteMixed view
Photo source: sideeffectsdoc.com
Told AFP that many of these molecules have never been tested in humans and that self-experiment stories shared online carry no scientific weight.
Source: Sud Radio / AFP, Aug 2026
Armelle RancillacWebsiteWarns against
Photo source: college-de-france.fr
Watch and read
Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.
5 Things to Know About the FDA's Peptide Reversal
Habiba Atta, writer
Covers the 2026 FDA peptide reversal, in which Selank is among about 14 peptides expected to move back to a compounding-eligible category despite thin evidence.
Explains Selank's current US regulatory status.
When options run out
Uses people turn to when standard treatment has failed.
Add-on to weight loss drug regimens
- Who
- People on GLP-1 weight loss drugs who add Selank or Semax hoping to improve results.
- Evidence
- Trade press reports the practice. Neither peptide has shown safety or effectiveness in clinical trials and neither is FDA approved.
Source: PharmaVoice, 2026-04
Legal last-resort routes
Expanded access (compassionate use)
For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.
Right to Try
For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.
Source: FDA, Right to Try
Trial finders
Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.
Source: NIH, finding a clinical trial
Personal import for serious conditions
FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.
Source: FDA, personal importation
Patient-specific compounding
When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.
Amino-acid sequence
Questions people ask
Does Selank work for anxiety?
The evidence is weak. In a 70-person open trial funded by the maker, adding Selank to a benzodiazepine raised the response rate from 23% to 40%, a difference that could be chance.
What is the difference between Selank and Semax?
Selank is a sibling of Semax from the same Russian institute. Selank is registered in Russia for anxiety and is sold elsewhere as a calming nasal spray that does not sedate.
What are the side effects of Selank?
There are no systematic safety data, and FDA says it lacks key information on safety in people. Users report tiredness and a mild effect that fades with use.
Is Selank legal in the US?
Its compounding nomination was withdrawn, and it is not on the list pharmacies may compound from. An advocacy group found it in declared US peptide imports in early 2026.
Your notebook
Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.
Sources
- Medvedev et al. 2015: Selank added to phenazepam (Korsakov Journal)
- Partnership for Safe Medicines: peptide import records (9 Jun 2026)
- FDA: bulk substances that may present significant safety risks
Structure: PubChem